Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Gains from Sales and Divestitures (2019 - 2025)

Lipocine (LPCN) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $3625.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Sales and Divestitures changed N/A year-over-year to $3625.0, compared with a TTM value of $3625.0 through Sep 2025, changed N/A, and an annual FY2020 reading of $628807.0, up 154.06% over the prior year.
  • Gains from Sales and Divestitures was $3625.0 for Q3 2025 at Lipocine, up from $2416.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $3625.0 in Q3 2025 and bottomed at $2416.0 in Q1 2025.